Pure Global AI
NCT06283654Completed

Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation

Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation: a Historically Controlled Prospective Trial
Amsterdam UMC, location VUmcClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Atrial Fibrillation
Drug/Device/Intervention
1-lead ECG
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Amsterdam UMC, location VUmc
Location
Amsterdam, Netherlands
Timeline & enrollment
Phase
N/A
Start date
Sep 30, 2018
End date
Jan 31, 2023
Enrollment
204 participants
Primary outcome

ED visits

Summary

In our study, we explored a new approach to manage atrial fibrillation, a disease that
 affects millions worldwide. Our goal was to see if using a simple handheld ECG device for
 monitoring heart rhythm could help patients avoid unnecessary visits to the emergency
 department (ED) after undergoing a common procedure known as pulmonary vein isolation (PVI).
 This procedure is often used to treat AF, but following it patients frequently visit the ED
 due to concerns about their heart rhythm, which can strain healthcare resources. We provided
 a group of patients with a 1-lead ECG device , which allows users to check their heart rhythm
 at any time. We compared the ED utilization over a year with that of patients who received
 standard care after PVI. Our hope was that by using the 1-lead ECG device, patients could
 better manage their condition from home and only seek medical help when truly necessary.

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06283654
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06283654 through Pure Global AI's free database. This phase not specified trial is sponsored by Amsterdam UMC, location VUmc and is currently Completed. The study focuses on Atrial Fibrillation. Target enrollment is 204 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.